Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

facility under the Credit Agreement from $50 million to $80 million.

Third Quarter Fiscal Year 2013 OutlookThe results of Oclaro for the third quarter of fiscal 2013, which ends March 30, 2013, are expected to be:

  • Revenues in the range of $140 million to $155 million.
  • Non-GAAP gross margin in the range of 10% to 14%.
  • Adjusted EBITDA in the range of negative $25 million to negative $13.5 million.
  • The foregoing guidance is based on current expectations. These statements are forward looking, and actual results may differ materially. Please see the Safe Harbor Statement in this earnings release for a description of certain important risk factors that could cause actual results to differ, and refer to Oclaro's most recent annual and quarterly reports on file with the Securities and Exchange Commission (SEC) for a more complete description of these risks. Furthermore, our outlook excludes items that may be required by GAAP, including, but not limited to, restructuring and related costs, acquisition or disposal related costs, any additional flood-related expenses, expenses or income from certain legal actions, settlements and related costs outside our normal course of business, impairments of other long-lived assets, depreciation and amortization, extraordinary items, as well as the expensing of stock options and restricted stock grants. We do not intend to update this guidance as a result of developments occurring after the date of this release.

    Conference CallOclaro will hold a conference call to discuss financial results for the second quarter of fiscal 2013 today at 1:30 p.m. PT/4:30 p.m. ET. To listen to the live conference call, please dial (480) 629-9665. A replay of the conference call will be available through February 7, 2013. To access the replay, dial (858) 384-5517. The passcode for the replay is 4593179. A webcast of this call and a supplemental presentation will be available in the investor sec
    '/>"/>

    SOURCE Oclaro, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
    2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
    3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
    4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
    5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
    6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
    7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
    8. Kemwell Announces Successful Pre-NDA US FDA Inspection
    9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
    10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
    11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)...  NeuroSigma, Inc. (NeuroSigma), a California ... non-invasive Monarch ™ eTNS™ Therapy for ... that enrollment has begun in a pediatric open label ... therapy for the treatment of Lennox-Gastaut Syndrome (LGS). ... View-UCLA Medical Center in Sylmar, California ...
    (Date:7/22/2014)... England , July 22, 2014 ... development and device company focused on solid dose ... its novel solid formulation of octreotide acetate achieved ... it with the currently marketed liquid product (Sandostatin®). ... transfer the formulation production process to a contract ...
    (Date:7/21/2014)... N.J. , July 21, 2014  Champions Oncology ... advanced technology solutions and services to personalize the development ... report its financial and operational results for the fourth ... Thursday, July 24, 2014, after market close. ... the results that day at 4:30 p.m. EDT (1:30 ...
    Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
    ... 10, 2011 USANA Health Sciences, Inc. (NYSE: ... nutritional gaps are common in the average American diet and ... those gaps.  However, USANA scientists and advising physicians caution that ... Dietary Guidelines for Americans, 2010 and ...
    ... MATEO, Calif., Feb. 10, 2011 AlphaDetail, a leader ... biotech industries, reported a 30% increase in revenue in ... time in the company,s history. "Our clients ... provides the marketing research solutions that get at the ...
    Cached Medicine Technology:USDA Recognizes Benefit of Supplements in New Dietary Guidelines But Doesn't Go Far Enough 2AlphaDetail Revenue Soars 30% in 2010 2
    (Date:7/22/2014)... 2014 Visitors to the Radiometer booth ... July 29-31) will have the opportunity to learn from ... errors. Radiometer will host two sessions of each presentation ... Individualized Quality Control Plan (IQCP) for Blood Gas Testing, ... Sy Albakri, PhD, Clinical and Scientific Affairs Manager, Radiometer ...
    (Date:7/22/2014)... (PRWEB) July 22, 2014 Recently, 2014quinceaneradresses.com, ... has announced its latest assortment of blue and ... promotional prices on these special Quinceanera gowns, hoping to ... before July 30 can get a discounted price, up ... very glad to announce these new items. As one ...
    (Date:7/22/2014)... July 22, 2014 MyDiettogo ... well as community discussion forums, to make it easier ... health. Customers now can track their Diet-to-Go meals, change ... journey, all from their computer or smart phone. Diet-to-Go ... staff Nutritionist and Certified Health Coach. , According to ...
    (Date:7/22/2014)... 22, 2014 Industry-leading health business information ... release of Specialty Pharmacy Trends and Strategies: 2014 ... provides a comprehensive overview of the current state of ... strategies and tactics for:, , Specialty ... utilization concerns — including details of coinsurance levels by ...
    (Date:7/22/2014)... 22, 2014 To help offset the ... Therapy Training Institute of Miami is reducing the ... award-winning model Brief Strategic Family Therapy™. To implement ... a variety of funding sources, but those opportunities seem ... situation we want to help relieve somehow,” said the ...
    Breaking Medicine News(10 mins):Health News:Radiometer Features Booth Presentations On IQCP and Blood Gas Preanalytics at the 2014 AACC Clinical Lab Expo 2Health News:Blue and White Quinceanera Dresses at Low Prices Offered by 2014quinceaneradresses.com 2Health News:Diet-to-Go Introduces New Online and Mobile Weight-Loss Tools, with Apps for iPhone and Android 2Health News:Latest Edition of Annual Book Provides Comprehensive Overview of the Specialty Pharmacy Arena 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 2Health News:FTTIM Makes Brief Strategic Family Therapy Training a Little More Affordable 3
    ... combines bone marrow removal and injection of a hormone ... locations in the body, it was reported by Yale ... "This could radically change the way patients are currently ... traumatic long bone fractures," said senior author Agns ...
    ... AUBURN HILLS, Mich., Feb. 14 Armed with the ... a hefty price tag, a,major automotive company has taken ... The program is 10 times more effective and ... and is expected to,translate into significant healthcare expense savings., ...
    ... this problem is an important step before moving on to ... major concern with using stem cells to treat disease has ... cells might cause cancer, but now a group of scientists ... groups of researchers -- one in Japan and one in ...
    ... Goes to Conference Committee Next Before Final Version is,Voted ... repayment,program for professions of "national need" will include occupational,therapists ... agreed to by the,Senate. AOTA staff worked fast and ... late last week. AOTA was able to have Representative ...
    ... Eye Care & Dental Professionals Kick off Year-Long Initiative, ... in Buffalo,NY, the world is about to become brighter. ... by volunteers recently at the first of,Davis Vision,s 2008 ... Bills, the event attracted 100 children,ages 5 through 16 ...
    ... Boston Scientific,Corporation (NYSE: BSX ) today announced that ... Venous Access businesses to Avista Capital,Partners for $425 million ... December 13, 2007., The Company expects to record ... quarter of 2008 in connection with the,transaction., "The ...
    Cached Medicine News:Health News:Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 2Health News:Chrysler Goes Holistic to Revolutionize Back Pain Care in the Workplace 3Health News:Scientists Show Stem Cells Don't Cause Cancer 2Health News:Scientists Show Stem Cells Don't Cause Cancer 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 2Health News:Davis Vision, United Concordia Free Clinic Promotes Children's Eye and Dental Health 3Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 2Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 3Health News:Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners 4
    ... Vitrectomy Lenses are a family of single-use direct ... of a particular region of the retinal surface ... less than 1 gram and is formed and ... of a human cornea. Lenses come in boxes ...
    ... The AFX Lens is a ... use in an air-filled eye. ... as a primary air-fluid exchange ... and sutureless design make it ...
    ... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
    ... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
    Medicine Products: